

# Kashiv BioSciences Corporate Overview

---

July 2020



# Kashiv BioSciences Corporate Overview

## Overview:

- Kashiv BioSciences, founded in 2011, is a premier fully integrated specialty biopharmaceutical company offering next-generation drug delivery technologies and an advanced pipeline of oral & biosimilar drugs.
- Kashiv Specialty Pharmaceuticals (KSP) is a wholly-owned subsidiary of Kashiv BioSciences, formed to develop complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs.
- The company's scientific and business executives have extensive industry experience in developing advanced drug delivery technologies and making novel products.
- R&D and cGMP manufacturing sites are located in New Jersey, Chicago, and India
- 200+ employees
- Four business units:
  - KSP Drug Delivery Platforms
  - KSP 505(b)(2) Products
  - Biosimilars
  - Prodrugs

## Locations:



### **KSP, Bridgewater, NJ**

- Oral Solid R&D and Manufacturing



### **Piscataway, NJ**

- Mammalian cell line Development and Manufacturing



### **Chicago, IL**

- Microbial cell line Development and Manufacturing



### **Ahmedabad, Gujarat, India**

- State-of-the-art R&D facility
- Injectable Manufacturing

# Four Business Units

## KSP Drug Delivery



Next-generation technologies for improved oral drug delivery

- GRANDE™ – gastric retention systems
- KRONOTEC™ – timed release technology

## KSP 505(b)(2) Products



Portfolio of five differentiated clinical-stage products in development targeting orphan and severe disease e.g. Myasthenia Gravis, Dystonia, Hypothyroidism, ADHD, & Parkinson's


## Biosimilars



Fully Integrated Development Infrastructure

- Products in late-stage development
- Mammalian and Bacterial Platforms

## Prodrugs




- Initial targets are known drugs requiring improved safety and efficacy
- Lead candidates in preclinical development

# Advanced Drug Delivery Platforms

## KRONOTEC™


MODIFIED RELEASE TECHNOLOGY



- **Application:** Modifies drug kinetics to mimic physiological patterns and targets chronological release when required


## GRANDE™

GASTRIC RETENTION SYSTEM



- **Application:** Enables sustained 12-24 hour delivery for drugs with site-specific absorption in the upper GI tract

# Kashiv BioSciences Development Pipeline



\*Orphan Disease

■ Biosimilar

■ 505(b)(2)

■ Prodrug

The logo for KASHIV BIOSCIENCES features a vertical bar on the left composed of seven horizontal segments in shades of blue and teal. To the right of this bar, the word "KASHIV" is written in a large, bold, dark blue sans-serif font. Below "KASHIV", the word "BIOSCIENCES" is written in a smaller, dark blue sans-serif font, with each letter spaced out.

**KASHIV**  
BIOSCIENCES

[KASHIVBIOSCIENCES.COM](http://KASHIVBIOSCIENCES.COM)

CONFIDENTIAL